Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Tranexamic Acid and Terlipressin for Emergency Treatment of Mild to Severe Hemoptysis in Patients Without Cystic Fibrosis

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of hemoptysis, which is the coughing up of blood from the lungs or airways. The trial will explore the effectiveness of two medications: tranexamic acid and terlipressin. Both medications will be administered through inhalation, which means they are breathed in using a device called a nebulizer. The purpose of the study is to determine how well these treatments can control mild to severe hemoptysis in patients during the first three days of hospitalization.

Participants in the study will receive either tranexamic acid, terlipressin, or a placebo, which is a substance with no active medication. The trial will monitor the patients to see if the hemoptysis resolves completely or partially without needing any additional medical procedures. Complete resolution means the bleeding stops entirely within three days, while partial resolution means the bleeding reduces significantly.

The study will also track other outcomes, such as the total amount of blood coughed up, the need for further treatments, and any side effects that may occur. This information will help researchers understand the potential benefits and risks of using these medications for treating hemoptysis. The trial is expected to continue until early 2026, with the goal of providing valuable insights into the management of this condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be required to provide a signed informed consent. This confirms your understanding and agreement to participate in the trial.

    You must meet certain criteria, such as being between 18 and 90 years old, having mild to severe hemoptysis for less than 7 days, and having been admitted to the emergency department or ICU for less than 12 hours.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to evaluate your condition. This includes measuring the total expectorated blood volume, which should range from 50 ml to 200 ml.

    Your eligibility for the trial will be confirmed based on this assessment.

  3. Step 3

    Treatment allocation

    You will be randomly assigned to receive one of the following treatments: tranexamic acid, terlipressin, or a placebo (normal saline).

    All treatments are administered through inhalation.

  4. Step 4

    Treatment administration

    The treatment will be administered to you for the immediate control of hemoptysis within the first 3 days of hospitalization.

    The dosage and frequency of administration will be determined by the medical team overseeing the trial.

  5. Step 5

    Monitoring and evaluation

    Your condition will be closely monitored to assess the effectiveness of the treatment. This includes checking for complete or partial resolution of hemoptysis.

    Complete resolution is defined as the absence of recurrence within 3 days, while partial resolution is defined as recurrence of less than 50 ml within the first 3 days.

  6. Step 6

    Follow-up

    You will be followed up to evaluate the long-term outcomes, such as the rate of hemoptysis recurrence within 30 days and any adverse events.

    The medical team will also monitor for any specific adverse events, such as acute myocardial ischemia or bronchospasm.

Who can join the trial?

7 criteria

  • Patients must be over 18 years and under 90 years old.
  • Must have mild to severe hemoptysis (coughing up blood) that has been happening for less than 7 days.
  • The total amount of blood coughed up should be between 50 ml to 200 ml.
  • Must have been admitted to the emergency department or ICU for less than 12 hours.
  • Must have social security affiliation.
  • Must have signed informed consent, which means agreeing to participate after understanding the study.
  • For women who can have children, they must use effective contraception methods such as oral estrogen-progestin, oral progestin, progestin implants, or any type of intrauterine device (IUD).

Who cannot join the trial?

1 criterion

  • Patients with **hemoptysis** (coughing up blood) from any cause, except for those with **cystic fibrosis**.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Tranexamic Acid

    is a medication used to help control bleeding. In this trial, it is being tested in an inhaled form to see if it can quickly stop bleeding in the lungs, known as hemoptysis, which can range from mild to severe. The goal is to see if it can effectively control the bleeding within the first three days of hospitalization.

  • Terlipressin

    is another medication being tested in this trial. It is also used to manage bleeding, but it works differently from Tranexamic Acid. In this study, it is being used in an inhaled form to determine if it can help stop bleeding in the lungs quickly and effectively during the initial days of hospital treatment for hemoptysis.

What is already known about the treatment

  • Tranexamic Acid

    Tranexamic Acid is administered as an inhaled medication, meaning it is breathed in through the mouth using a special device. It is currently being studied in clinical trials for its effectiveness in treating hemoptysis, which is coughing up blood, from various causes except cystic fibrosis. The medication works by helping to prevent the breakdown of blood clots, which can help stop bleeding. It is classified as an antifibrinolytic agent, which means it helps to stabilize blood clots.

  • Terlipressin

    Terlipressin is also administered as an inhaled medication, similar to Tranexamic Acid, and is being evaluated in clinical trials for its potential to control hemoptysis, or coughing up blood, from different causes excluding cystic fibrosis. This medication acts by narrowing blood vessels, which can reduce blood flow and help control bleeding. It belongs to a class of drugs known as vasopressors, which are used to increase blood pressure and reduce bleeding.

Investigated diseases

Hemoptysis – Hemoptysis is the medical term for coughing up blood from the respiratory tract. It can originate from the lungs or bronchial tubes and is often a symptom of an underlying condition. The blood can vary in color from bright red to rust-colored, depending on the source and duration of bleeding. Hemoptysis can range from mild, with small amounts of blood, to severe, with significant blood loss. The progression of hemoptysis depends on its cause, which can include infections, lung diseases, or trauma. It requires medical evaluation to determine the underlying cause and appropriate management.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-515010-40-00Protocol codeAPHP200043Estimated enrolment315 patientsSponsorAssistance Publique Hopitaux De Paris

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).